title: Clusterin confers paclitaxel resistance in cervical cancer.
abstract: OBJECTIVE
  To measure clusterin expression in cervical cancer tissues and cell lines and to evaluate whether clusterin confers resistance to paclitaxel in cervical cancer cells.
  
  
  METHODS
  Immunohistochemical staining for clusterin was performed on 15 normal cervical tissues and 32 primary cervical cancer tissues, and clusterin expression in cervical cancer cell lines was quantified by Western blotting. The correlation between clusterin expression level and paclitaxel IC50 in cervical cancer cell lines was evaluated. The effect of clusterin siRNA on paclitaxel resistance was evaluated by XTT assays.
  
  
  RESULTS
  Cervical cancer tissues expressed significantly higher levels of clusterin than did normal cervical tissues (4.08 vs. 1.35, P<0.05). Clusterin expression levels were correlated with paclitaxel resistance in cervical cancer cell lines, and transfection of clusterin siRNA into HeLaS3 cells significantly decreased their resistance to paclitaxel (P<0.05).
  
  
  CONCLUSIONS
  Our finding that clusterin expression was significantly higher in cervical cancer than in normal cervical tissues suggests that clusterin may confer paclitaxel resistance in cervical cancer cells.
authors.affiliation: Department of Obstetrics and Gynecology, St. Vincent's Hospital, The Catholic University of Korea, 93 Gi-dong, Paldal-ku, Suwon, Republic of Korea. dcpark@catholic.ac.kr
authors.forename: Dong Choon
authors.initials: DC
authors.lastname: Park
authors.forename: Seung Geun
authors.initials: SG
authors.lastname: Yeo
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Shin
authors.forename: Samuel C
authors.initials: SC
authors.lastname: Mok
authors.forename: Dae Hoon
authors.initials: DH
authors.lastname: Kim
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016022:Case-Control Studies; D045744:Cell Line, Tumor / Q000187:drug effects; D051152:Clusterin / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D020128:Inhibitory Concentration 50; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology* / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D034741:RNA, Small Interfering / Q000032:analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D051152:Clusterin; D034741:RNA, Small Interfering; D017239:Paclitaxel